United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 22,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $478.58, for a total transaction of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00.
• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total value of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $417.50, for a total transaction of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00.

United Therapeutics Stock Down 1.3%

NASDAQ UTHR traded down $6.71 on Tuesday, hitting $496.19. The company’s stock had a trading volume of 235,802 shares, compared to its average volume of 575,789. The company’s 50-day moving average is $472.78 and its 200 day moving average is $390.12. The firm has a market cap of $21.36 billion, a PE ratio of 18.80, a PEG ratio of 5.04 and a beta of 0.86. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.39 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $29,000. WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB grew its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Finally, Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics during the third quarter valued at approximately $44,000. 94.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on UTHR shares. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday. Finally, Royal Bank Of Canada upped their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.